2015
Peter Attia says he has taken an injectable PCSK9 inhibitor every two weeks since about 2015.
“I probably started in 2015, so it's an injectable drug. I take it every two weeks and it's a called a PCSK9 inhibitor”
Topic
7 facts from 4 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.
2015
Peter Attia says he has taken an injectable PCSK9 inhibitor every two weeks since about 2015.
“I probably started in 2015, so it's an injectable drug. I take it every two weeks and it's a called a PCSK9 inhibitor”
2023
In a phase two study, the highest dose of Merck's oral PCSK9-targeting drug reduced LDL cholesterol by about 60%.
“basically, the highest dose reduced patients' LDL or bad cholesterol by about 60 % with a pill.”
Undated
Daphne Koller cites PCSK9 as a target discovered through rare familial cholesterol variants whose drugs also help patients without those variants.
“A great example of that is the poster child here, which is PCSK9, where it was discovered in a rare familial variant in hypercholesterolemia on the one hand, familial hypercholesterolemia, familial hypocholesterolemia on the other, sort of showing this beautiful dose response.”
Undated
Peter Attia credits Helen Hobbs with discovering mutations in the PCSK9 gene, which codes for a protein that degrades LDL receptors, in people with familial hypercholesterolemia.
“she discovered this mutation in, uh, a gene for PCSK9 that codes for a protein that degrades LDL receptors.”
Undated
Aris Baras says Dallas Heart Study participants with loss-of-function PCSK9 variants had 90 percent lower rates of heart attacks and very low bad cholesterol.
“And those people had 90 % lower rates of heart attacks and very low levels of bad cholesterol.”
Undated
Ben Comer says Merck has a small-molecule product targeting PCSK9.
“Merck's got a small molecule product now targeting PCSK9.”
Undated
Aris Baras says the protective PCSK9 variant is 10 to 100 times more common in African-Americans than in other groups.
“So that protective human genetics mutation in PCSK9, I forget the exact number, 10 times, 100 times more common in African-Americans than in every other type of person.”
Episodes